Top

Published in:

01-04-2020 | Research Paper

A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence

Authors: Jingni He, Zhong Tian, Xu Yao, Baiyu Yao, Yuan Liu, Jiapeng Yang

Published in: Clinical & Experimental Metastasis | Issue 2/2020

Abstract

The papillary thyroid carcinoma (PTC) usually shows an excellent prognosis. But some patients suffer recurrence after treatment. Recent progress in RNA sequencing (RNA-Seq) allows us to explore whole-transcriptomic gene expression profiles to develop RNA-seq based predictive model for stratifying the risk of recurrence of PTC. RNA-seq and clinical data from The Cancer Genome Atlas thyroid carcinoma cohort were divided chronologically into a training cohort (before 2011, n = 240) and a validation cohort (after 2011, n = 239). A risk score model was developed in training cohort using univariate Cox analysis followed by stepwise multivariate Cox analysis, and assessed in the validation cohort. Univariate and multivariate analyses identified five independent predictive genes (TOP2A, RP11-180M15.7, RP11-635N19.1, PROSER3, and TMEM139) significantly (p < 0.05) associated with recurrence-free survival of PTC. The proposed risk score model defined by these five genes was able to divide patients into high-risk and low-risk groups with significantly different recurrence risk in both training cohort [hazard ratio (HR) 6.62, 95% confidence interval (CI) 3.16–13.86] and validation cohort [HR 3.40, 95% CI1.29–8.94). Furthermore, the model is independent of clinicopathologic factors and demonstrated better predictive performance than other clinical covariates in PTC patients with no distant metastasis. Our results indicate that TOP2A, RP11-180M15.7, RP11-635N19.1, PROSER3, and TMEM139 are potential independent predictive genes for the recurrence of PTC and the proposed RNA sequencing-based model has significant predictive value and may improve recurrence risk stratification for early-stage PTC patients.

Available only for authorised users

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133PubMedPubMedCentralCrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMed

Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140(4):317–322PubMedCrossRef

Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS (2011) Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21(2):125–134PubMedPubMedCentralCrossRef

Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A (2018) Overall survival of papillary thyroID carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg 42(3):615–622PubMedPubMedCentralCrossRef

Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338(5):297–306PubMedCrossRef

Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36(6):1274–1278PubMedCrossRef

Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12):1341–1349PubMedPubMedCentralCrossRef

Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ (2010) Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20(2):147–152PubMedCrossRef

10.

Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM (2012) Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol 77(1):132–138CrossRef

11.

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMedCrossRef

12.

Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM (2013) Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 23(11):1401–1407PubMedCrossRef

13.

Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F (2011) Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165(3):441–446PubMedCrossRef

14.

Pathak KA, Mazurat A, Lambert P, Klonisch T, Nason RW (2013) Prognostic nomograms to predict oncological outcome of thyroid cancers. J Clin Endocrinol Metab 98(12):4768–4775PubMedCrossRef

15.

Lang BH-H, Wong CK (2015) Validation and comparison of nomograms in predicting disease-specific survival for papillary thyroid carcinoma. World J Surg 39(8):1951–1958PubMedCrossRef

16.

Lang BH, Wong CK, Yu HW, Lee KE (2016) Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma. Head Neck 38(S1):E1256–E1263PubMedCrossRef

17.

Jianyong L, Jinjing Z, Zhihui L, Tao W, Rixiang G, Jingqiang Z (2018) A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28(3):301–310PubMedCrossRef

18.

Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321(1):86–93PubMedCrossRef

19.

Vuong HG, Altibi AMA, Duong UNP, Hassell L (2017) Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol 87(5):411–417CrossRef

20.

Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C (2015) Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33(1):42–50PubMedCrossRef

21.

Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C (2012) The BRAF V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398PubMedCrossRef

22.

Li C, Lee KC, Schneider EB, Zeiger MA (2012) BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97(12):4559–4570PubMedPubMedCentralCrossRef

23.

Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754–E765PubMedPubMedCentralCrossRef

24.

Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32(25):2718–2726PubMedPubMedCentralCrossRef

25.

Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, Miyauchi A, Eguchi S, Yoshiura KI, Yamashita S, Nagayasu T, Mitsutake N (2019) TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. Thyroid 29(8):1105–1114PubMedCrossRef

26.

Vuong HG, Duong UN, Altibi AM, Ngo HT, Pham TQ, Tran HM, Gandolfi G, Hassell L (2017) A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect 6(3):R8–Rr17PubMedPubMedCentralCrossRef

27.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885–4893PubMedPubMedCentralCrossRef

28.

Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, Wang Y, Ji Q (2016) Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer. Sci Rep 6:36973PubMedPubMedCentralCrossRef

29.

Sondermann A, Andreghetto FM, Moulatlet ACB, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG, Severino P (2015) MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. Clin Exp Metastasis 32(6):521–530PubMedCrossRef

30.

Wang M, Lindberg J, Klevebring D, Nilsson C, Lehmann S, Grönberg H, Rantalainen M (2018) Development and validation of a novel RNA sequencing–based prognostic score for acute myeloid leukemia. J Natl Cancer Inst 110(10):1094–1101PubMedPubMedCentralCrossRef

31.

Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM (2017) Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 109(1):djw200CrossRef

32.

Zhou M, Zhang Z, Zhao H, Bao S, Cheng L, Sun J (2018) An immune-related six-lncRNA signature to improve prognosis prediction of glioblastoma multiforme. Mol Neurobiol 55(5):3684–3697PubMed

33.

Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31(9):1172–1181PubMedPubMedCentralCrossRef

34.

The Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690CrossRef

35.

Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I (2015) TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44(8):e71–e71PubMedPubMedCentralCrossRef

36.

Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S (2012) GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 22(9):1760–1774PubMedPubMedCentralCrossRef

37.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q (2015) Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell 28(4):529–540PubMedPubMedCentralCrossRef

38.

Li J, Tibshirani R (2013) Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res 22(5):519–536PubMedCrossRef

39.

Bozdogan H (1987) Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions. Psychometrika 52(3):345–370CrossRef

40.

Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110(8):803–811PubMedPubMedCentralCrossRef

41.

Wagenmakers EJ, Farrell S (2004) AIC model selection using Akaike weights. Psychon Bull Rev 11(1):192–196PubMedCrossRef

42.

Lee S, Jung S-R, Heo K, Byl JAW, Deweese JE, Osheroff N, Hohng S (2012) DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Proc Natl Acad Sci USA 109(8):2925–2930PubMedCrossRefPubMedCentral

43.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12(12):1134–1142PubMedCrossRef

44.

Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM (2013) Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treat 137(1):57–67PubMedCrossRef

45.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku S-Y, Sjöström M, Alshalalfa M, Erho N (2017) TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res 23(22):7072–7083PubMedPubMedCentralCrossRef

46.

Ito F, Furukawa N, Nakai T (2016) Evaluation of TOP2A as a predictive marker for endometrial cancer with taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer 26(2):325–330PubMedCrossRef

47.

Chen D, Maruschke M, Hakenberg O, Zimmermann W, Stief CG, Buchner A (2017) TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology 102:265. e261-265. e267PubMedCrossRef

48.

Pita J, Banito A, Cavaco B, Leite V (2009) Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 101(10):1782–1791PubMedPubMedCentralCrossRef

49.

Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16(2):161–175PubMedCrossRef

50.

Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV (2016) Non-coding RNAs in thyroid cancer. Endocr Pathol 27(1):12–20PubMedCrossRef

51.

Pan W, Zhou L, Ge M, Zhang B, Yang X, Xiong X, Fu G, Zhang J, Nie X, Li H (2016) Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum Mol Gen 25(9):1875–1884PubMedCrossRef

52.

Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV (2018) Long non-coding RNA Linc-ROR is upregulated in papillary thyroid carcinoma. Endocr Pathol 29(1):1–8PubMedCrossRef

Title: A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence
Authors: Jingni He
Zhong Tian
Xu Yao
Baiyu Yao
Yuan Liu
Jiapeng Yang
Publication date: 01-04-2020
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 2/2020
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-10011-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Sentinel node tumor burden in prediction of prognosis in melanoma patients

Development of a novel murine model of lymphatic metastasis

Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis

Curative-intent pancreas resection for pancreatic metastases: surgical and oncological results

Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer

Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer